Production of the Ramoplanin Activity Analogue by Double Gene Inactivation

Jungang Han1, Junsheng Chen1,2, Lei Shao1*, Junliang Zhang1, Xiaojing Dong1, Pengyu Liu1, Daijie Chen1*

1 State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, 1320 West Beijing Rd., Shanghai 200040, China, 2 School of Pharmacy, Shanghai Jiao Tong University, 800 Dongchuan Rd., Minhang District, Shanghai 200240, China

Abstract

Glycopeptides such as vancomycin and telavancin are essential for treating infections caused by Gram-positive bacteria. But the dwindling availability of new antibiotics and the emergence of resistant bacteria are making effective antibiotic treatment increasingly difficult. Ramoplanin, an inhibitor of bacterial cell wall biosynthesis, is a highly effective antibiotic against a wide range of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus, vancomycin-intermediate resistant Clostridium difficile and vancomycin-resistant Enterococcus sp. Here, two tailoring enzyme genes in the biosynthesis of ramoplanin were deleted by double in-frame gene knockouts to produce new ramoplanin derivatives. The deschlororamoplanin A2 aglycone was purified and its structure was identified with LC-MS/MS. Deschlororamoplanin A2 aglycone and ramoplanin aglycone showed similar activity to ramoplanin A2. The results showed that α-1,2-dimannosyl disaccharide at Hpg11 and chlorination at Chp17 in the ramoplanin structure are not essential for its antimicrobial activity. This work provides new precursor compounds for the semisynthetic modification of ramoplanin.

Introduction

Antibiotic resistance has increasingly become more serious in the clinic. The β-lactamase production in Gram-positive bacteria render several β-lactam antibiotics ineffective. In the United States more than 94,000 people are infected and about 19,000 are killed by methicillin-resistant Staphylococcus aureus (MRSA) every year. As “The last line of resistant Gram-positive bacterial antibiotic”, vancomycin also was seriously challenged with the emergence of vancomycin-resistant Enterococcus VRE in recent years [1]. Ramoplanin (1) which was isolated from the fermentation broth of Actinoplanes sp. ATCC33076 more than 20 years ago is a highly effective antibiotic against a wide range of Gram-positive bacteria, including MRSA, vancomycin-intermediate resistant Clostridium difficile and VRE [2,3,4]. Ramoplanin inhibits the biosynthesis of bacterial cell wall. Previous studies have shown that ramoplanin interferes with the transglycosylase-catalyzed extracellular polymerization of Lipid II to block the transglycosylation step of peptidoglycan biosynthesis [5,6]. As an oral antibiotic, ramoplanin is currently is in phase III clinic trials for the treatment of Clostridium difficile infection (CDI) and prevention of VRE infection [7].
Structurally, ramoplanin, a lipoglycodepsipeptide compound, contains 17 amino acids joined by a lactone linkage between a beta hydroxyl group on a lactone acid 2 (OHAsn2) and the carboxyl terminus of amino acid 17 (Chp17) (Fig 1). Ramoplanin contains an α-1,2-dimannosyl group attached by an α-glycosidic linkage to the phenol of amino acid 11 and a mono-chlorinated hydroxyphenylglycine in position 17. This residue is one of the three hydrophobic groups containing the Chp17-Hpg3-Phe9 aryl core. Non-ribosomal peptide synthetases (NRPSs) catalyzed the biosynthesis of Non-ribosomal peptides (NRPs) by the consecutive condensation of amino acids and other carboxylic acids in bacteria [8,9]. The ramoplanin biosynthesis gene cluster was isolated and analyzed from Actinoplanes sp. ATCC33076 in 2002 [10]. The analysis showed that the consecutive action of four NRPSs (ram12, 13, 14 and 17) assembled the peptide core of ramoplanin containing a mixture of L and D amino acids (nine L, seven D) as well as several nonproteinogenic side chains [11]. To investigate the glycosylation mechanism in ramoplanin biosynthesis ram29 was inactivated and mutant strain A.C/S1001 was shown to produce the ramoplanin aglycone (2), suggesting that Ram29 is responsible for incorporation of the mannose sugars in ramoplanin [12]. Herein we described the double inactivation of ram29 gene coding mannosyltransferase and ram20 gene coding halogenase in Actinoplanes sp. ATCC33076 and identification of ramoplanin derivative.

Materials and Methods

Materials, DNA isolation, manipulations and sequencing

Bacterial strains and plasmids used in this study are listed in Table 1. Actinoplanes sp. ATCC33076, E.coli DH5α, E. coli ET12567, pKC1139 plasmid and Deschlororamoplanin A2

Fig 1. Structure of ramoplanin and its derivative.
(4) were obtained from standard commercial sources. DNA isolation and manipulation were performed by standard methods [13,14]. Primer synthesis and DNA sequencing were performed at Shanghai Mapbio Biotechnology Co.

### Inactivation of ram20 in A.CJS1001 and genotype analysis of mutant

To inactivate ram20 in A. CJS1001, two homolog arms containing the upstream and downstream of ram20 were PCR amplified from *Actinoplanes* sp. ATCC33076 genomic DNA and inserted into the shuttle vector pKC1139. The 1.1-kb fragment was amplified using primers 5’-AAAAAGCTTCCGACGATGACGATCCGTGTCC-3’ and 5’-AAATCTAGACGGTGAAGGTGAA-3’. These primers were designed to amplify a 1.1-kb fragment containing the upstream and downstream of ram20, respectively. The amplified fragment was digested with HindIII and XbaI and cloned into the HindIII and XbaI sites of pSP72 to generate pJG1011. The purified PCR product was then digested with EcoRI and XbaI and then inserted into appropriately digested pSP72 to yield pJG1012. The identity of the PCR product with two homolog exchange arms (GenBank accession number AX417445) was confirmed by sequencing. The 1.1-kb HindIII/XbaI fragment and 1.1-kb EcoRI/XbaI fragment were then excised from pJG1011 and pJG1012 respectively, and inserted into pKC1139 prepared by digestion with HindIII and EcoRI to construct the in-frame inactivation plasmid pJG1013.

The resultant pJG1013 was then introduced into A. CJS1001 from *E. coli* ET12567 by intergeneric conjugation as previously described. For inactivation of ram20, apramycin-resistant colonies at 37°C were identified as the positive integrated mutants, with a single-crossover homologous recombination. These mutants were further cultured for three days in 3 ml liquid tryptic soy broth (TSB) for five rounds without apramycin. The genotypes of resultant apramycin-sensitive strains were confirmed by PCR amplification and sequencing, which led to identification of the recombinant strain A.CSL1015, in which the 534bp internal fragment was in-frame deleted.

### Production and preparation of ramoplanin and its derivative in fermentation cultures

*Actinoplanes* sp. ATCC 33076 and its mutant strains were fermented as previously described [12,17]. The fermentation broth was adjusted to pH 3.0 and extracted twice with an equal

### Table 1. Strains and plasmids used in this work.

| Strains or plasmids | Relevant features | Source or reference |
|---------------------|------------------|---------------------|
| **Strains**         |                  |                     |
| ATCC33076           | Wild type; ramoplanin producer | This Laboratory |
| A. CJS1001          | ATCC33076 derivative, with the ram29 gene in-frame deleted | [12] |
| A.CSL1015           | A. CJS1001 derivative with the ram20 gene in-frame deleted | This work |
| **E. coli**         |                  |                     |
| DH5α                | General cloning host | Invitrogen |
| ET12567             | Methylation deficient; Donor strain for conjugation between *E. coli* and *Actinoplanes* | [15] |
| **Plasmids**        |                  |                     |
| pSP72               | *E. coli* general cloning vector, AmpR | Promega |
| pKC1139             | *E. coli—Streptomyces* shuttle vector; repR; OriT, AmR | [16] |
| pJG1011             | 1.1-kb PCR fragment containing the upstream of ram20 in pSP72 | This work |
| pJG1012             | 1.0-kb PCR fragment containing the downstream of ram20 in pSP72 | This work |
| pJG1013             | 1.1-kb left arm and 1.0-kb right arm of ram20 in pKC1139 | This work |

doi:10.1371/journal.pone.0154121.t001
volume of ethyl alcohol. The crude extract was applied to WQ NO.1 macroporous resin. The 30% ethanol eluent containing the target compound was concentrated using an Agilent reversed-phase column (ZORBAX Eclipse Plus C18 9.4×250mm, 5μm). The mobile phase was 0.4% ammonium formate/acetonitrile (68:32 v/v). The peaks containing the target compound were collected. The high density ammonium formate was eliminated using hydrophilic C18 packing. The 70% methanol eluent containing ramoplanin derivative was collected and dried. The highly purified ramoplanin derivative was used for analysis and bioassay.

Analysis of ramoplanin and its derivative
The fractions of ramoplanin and its derivative were detected by HPLC during the separation and purification processes performed on an Agilent reversed-phase column (ZORBAX Eclipse Plus C18 4.6×250mm, 5μm) using 0.1% ammonium formate/acetonitrile (65:35 v/v) as the mobile phases at 0.8 ml/min and 231nm. LC-MS and Tandem MS analyses were performed on LTQ XL combined with Agilent 1260 HPLC by the Instrumental Analysis Center of Shanghai Jiaotong University. The LC-MS² analyses with this instrument were performed with a Water CORTECS C18 2.1mm×100mm, 2.7μm column, using H₂O/CH₃CN (80:20) as mobile phase and with the ionization source run in positive mode. An MS² analysis was performed by selecting the doubly-charged ions (1116 for ramoplanin A2 aglycone and 1099 for deschlororamoplanin A2 aglycone respectively) as parent ions.

Evaluation of antibacterial activity
The activies of ramoplanin and its analogs against MRSA and VRE were determined using a liquid microdilution method. MIC values were detected according to the CLSI guidelines [18]. ATCC 25923 (methicillin-sensitive Staphylococcus aureus, MSSA), ATCC 43300 (methicillin-resistant Staphylococcus aureus, MRSA), ATCC 29212 (Enterococcus faecalis) and ATCC 51299 (vancomycin-resistant Enterococcus faecalis, VRE) were employed in this study. Ramoplanin and its analogs were dissolved in 30% methyl alcohol, which was also used as the negative control during the serial tests.

Results
Generation of the ram29 and ram20 double in-frame inactivated mutant
Two homolog exchange arms for inactivation of ram20, containing the upstream and downstream of ram20, were PCR amplified from Actinoplanes sp. ATCC33076 genomic DNA. The identity of the PCR product was confirmed by sequencing. A ram20 knockout strain of A. CJS1001 was constructed by double-crossover in-frame deletion of ram20 gene using pJG1013 to create strain A.CSL1015. The ram20 gene was inactivated by introducing a 456-bp in-frame deletion at the center of the gene to avoid any effects on the transcription of upstream and downstream ram20. PCR analysis of the genomic DNAs from the recombinant strains A. CJS1001 and A.CSL1015 showed that the ram29 and ram20 double in-frame inactivated mutant was successfully constructed (Fig 2).

Production and preparation of ramoplanin and its derivative in fermentation cultures
Actinoplanes sp. ATCC33076, A. CJS1001 and A.CSL1015 were grown in ramoplanin production medium under the same conditions for producing ramoplanin. Efficient culture cleanup for ramoplanin A2 and its derivative was performed on the fermentation broth of Actinoplanes sp. ATCC33076 and recombinant strains. HPLC of the sample revealed that the peaks of
Fig 2. Genotypes of recombinant strains and PCR analysis with the genomic DNA from Actinoplanes sp. ATCC33076 and its mutation as the template. (A) Genotypes of ATCC33076 and its mutants; (B) Using 5'- ATGGATGTCCCGAGGGTG -3' and 5'- TCAGGGTTGTCGCATCG -3' as primers, ram29 in-frame deletion PCR analysis of recombinant strains confirmed that they have the designed genotypes that the double-crossover homologous recombination event took place: 1.8 kb (lane 1) for wild type, 1.4 kb (lane 2) for A.CJS1001, and 1.4 kb (lane 3) for A.CSL1015. Using 5'- ATCTCGCTAGCACGGTGAAGG -3' and 5'- TGCACGCGGAGGAAAC -3' as primers, ram20 in-frame deletion PCR analysis of recombinant strains confirmed that they have the designed genotypes that the double-crossover homologous recombination event took place: 1.2 kb (lane 4) for wild type, 1.2 kb (lane 5) for A.CJS1001, and 0.75kb (lane 6) for A.CSL1015.

doi:10.1371/journal.pone.0154121.g002
Fig 3. HPLC analysis of ramoplanin and its derivative. (A) Ramoplanin A2 standard; (B) Production of ramoplanin A2 in *Actinoplanes* sp. ATCC33076; (C) Ramoplanin derivative production in *A.CJS*1001; (D) Ramoplanin derivative production in *A.CSL*1015.

doi:10.1371/journal.pone.0154121.g003
ramoplanin A2 and ramoplanin A2 aglycone were eliminated and a new analog, named ramoplanin X, with longer retention time than ramoplanin A2 and ramoplanin A2 aglycone for A. CSL1015. According to the standard curve of ramoplanin A2, its concentration in the broth of Actinoplanes sp. ATCC33076 was about 500 μg/ml. However, the yield of ramoplanin A2 aglycone was 100 μg/ml in the broth of A. CJS1001. Following isolation and purification from the A. CSL1015 culture broth, 5 mg of purified ramoplanin X was obtained.

Identification of ramoplanin derivative

As compared to A.CJS1001, A.CSL1015 did not produce no ramoplanin A2 aglycone m/z ([M+2H]^{2+}) = 1116 but a new major product, ramoplanin X, m/z ([M+2H]^{2+}) = 1099, which was 17Da less than the ion obtained with ramoplanin A2 aglycone (Fig 4).

The loss of 17Da may be attributed to the loss of the chlorine atom to the Hpg^{17}. To confirm this, the purified product as well as ramoplanin A2 aglycone was subjected to a tandem MS analysis. In the MS^2 spectra of ramoplanin A2 aglycone, fragment peptides y7 (Hpg^{11}-Cl-Hpg^{17}, m/z...
Antibacterial activity of ramoplanin derivative

Antibacterial activities of purified deschlororamoplanin A2 aglycone were compared with ramoplanin A2 and ramoplanin A2 aglycone. The MICs of ramoplanin A2, ramoplanin A2 aglycone and deschlororamoplanin A2 aglycone against ATCC 25923 (methicillin-sensitive Staphylococcus aureus, MSSA), ATCC 43300 (methicillin-resistant Staphylococcus aureus, MRSA), ATCC 29212 (Enterococcus faecalis) and ATCC 51299 (vancomycin-resistant Enterococcus faecalis, VRE) were determined. The results revealed that deschlororamoplanin A2 aglycone had equipotent activity of ramoplanin A2 against MRSA and VRE (Table 2).

Discussion

Nonribosomal peptides (NRPs) synthesized by non-ribosomal peptide synthetases are a diverse family of natural products with a broad range of biological activities and pharmacological

Table 2. Antibacterial activity of ramoplanin and purified its derivative.

| Microorganism       | MIC (µg/ml) |
|---------------------|-------------|
|                     | Ramoplanin A2 | Ramoplanin A2 aglycone | Deschlororamoplanin A2 aglycone | Deschlororamoplanin A2 | Enduracidin |
| Staphylococcus aureus ATCC43300 | 4 | 2 | 4 | 2 | 8 |
| Staphylococcus aureus ATCC25923 | 2 | 2 | 2 | 2 | 8 |
| Enterococcus faecalis ATCC29212 | 1 | 0.5 | 1 | 1 | 8 |
| Enterococcus faecalis ATCC51299 | 1 | 1 | 1 | 1 | 8 |

doi:10.1371/journal.pone.0154121.g002
properties. NRPs are often potent antibiotics, antifungals, antitumor, immunosuppressants, antiviral or antiparasitic therapeutics for clinical use [19]. The structural modification of NRPs is an important component of the natural product drug development process. Because of ramoplanin’s favorable antibacterial properties, efforts have been made to generate ramoplanin analogs by total or semi-synthesis of the natural compound [20,21,22]. But the complexity of ramoplanin structure makes chemical approaches difficult. Combinatorial biosynthesis can be defined as the application of genetic engineering to modify biosynthetic pathways of natural products in order to produce new and altered structures [23].

Previous studies showed that ramoplanin inhibited the intracellular glycosyltransferase (MurG)-catalyzed conversion of Lipid I (undecaprenyl-pyrophospho-N-acetylmuramyl-pentapeptide) to Lipid II (undecaprenyl-pyrophospho-N-acetylmuramyl-N-acetylglycosamine-pentapeptide) and blocked the transglycosylation step of peptidoglycan biosynthesis by interfering with the transglycosylase-catalyzed extracellular polymerization of Lipid II [5,24]. Ramoplanin contains an N-acyl chain which may insert into the bacterial membrane phospholipid bilayers and two positively charged ornithines (Orn) at positions 4 and 10 which may interact with anionic phospholipids that predominate in Gram-positive bacteria. Later studies showed the significance of disrupting the Chp\(^{17}\)-Asn\(^{2}\) lactone bond on antimicrobial activity, the requirement for cationic charge on ramoplanin’s two orn, and the importance of presentation of the Hpg\(^{14}\)-Orn\(^{10}\) PG binding sequence in a conformationally restrained manner [25,26,27,28].

Glycosylation is a frequently occurring NPRs antibiotics modification that was proven to be related to antibiotics activity. Chlorination is hypothesized to improve NPR dimerization that may in turn positively enhance antimicrobial activity [29,30]. Halogen in antibiotics also plays a role in determining adverse effects. For example, a halogen at position 8 in sparflaxacin and clinafloxacin caused serious phototoxicity [31]. In our studies, the deletion of \(\alpha\)-1,2-dimannosyl disaccharide attached to Hpg\(^{11}\) and chlorination at Chp\(^{17}\) of ramoplanin had no effect on its bioactivity against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus sp. (VRE) suggesting that \(\alpha\)-1,2-dimannosyl disaccharide at Hpg\(^{11}\) and chlorination at Chp\(^{17}\) of ramoplanin are not essential for its antimicrobial activity. The deletion of disaccharide group will increase lipid solubility and the logarithm of the octanol/water partition coefficient (LogP) of ramoplanin in favor of the permeability of the cell membrane. These will benefit the absorption and distribution of drugs in the body. The deletion of chlorine at Chp17 reduces the risk of potential toxicity. So, the fermentation products of mutants A. CJS1001 and A.CSL1015, ramoplanin aglycone and deschlororamoplanin A2 aglycone, also provide new precursor compounds for the semi-synthetic modification of ramoplanin. Halogenation and glycosylation of biosynthetic products may serve as powerful methods to introduce novel functionality into small molecules and may be used in combinatorial biosynthetic approaches in drug discovery.

**Author Contributions**

Conceived and designed the experiments: DC LS JC. Performed the experiments: JH JC LS. Analyzed the data: JH JC LS. Contributed reagents/materials/analysis tools: JZ XD PL. Wrote the paper: LS JC JH.

**References**

1. Urgently needed: new antibiotics. Lancet. 2009; 374: 1868.
2. Walker S, Chen L, Hu Y, Rew Y, Shin D, Boger DL. Chemistry and biology of ramoplanin: a lipoglyco depsipeptide with potent antibiotic activity. Chem Rev. 2005; 105: 449–476. PMID: 15700952
3. Cavalleri B, Pagani H, Volpe G, Selva E, Parenti F. A-16686, a new antibiotic from Actinoplanes. I. Fermentation, isolation and preliminary physico-chemical characteristics. J Antibiot (Tokyo). 1984; 37: 309–317.

4. Ciabatti R, Kettenring JK, Winters G, Tuan G, Zerilli L, Cavalleri B. Ramoplanin (A-16686), a new glycolipodepsipeptide antibiotic. II. Structure elucidation. J Antibiot (Tokyo). 1989; 42: 254–267.

5. Somner EA, Reynolds PE. Inhibition of peptidoglycan biosynthesis by ramoplanin. Antimicrob Agents Chemother. 1990; 34: 413–419. PMID: 2334153

6. Fang X, Niran J, Shin D, Rew Y, Boger DL. Total synthesis and examination of three key analogues of ramoplanin: a lipoglycodepsipeptide with potent antibiotic activity. J Am Chem Soc. 2004; 126: 1041–1043. PMID: 14746470

7. Sheikh S, Sturzu A, Kalbacher H, Klose U, Nagele T, Amin B, et al. Ramoplanin imaging conjugates—synthesis and evaluation. Med Chem. 2014; 10: 18–26. PMID: 23648784

8. Reynolds PE, Somner EA. Comparison of the target sites and mechanisms of action of glycopeptide and lipoglycodepsipeptide antibiotics. Drugs Exp Clin Res. 1990; 16: 385–389. PMID: 2151441

9. Fulco P, Wenzel RP. Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent. Expert Rev Anti Infect Ther. 2006; 4: 939–945. PMID: 17181409

10. Hoertz AJ, Hamburger JB, Gooden DM, Bednar MM, McCafferty DG. Studies on the biosynthesis of the lipodepsipeptide antibiotic Ramoplanin A2. Bioorg Med Chem. 2012; 20: 859–865. doi: 10.1016/j.bmc.2011.11.022 PMID: 22222159

11. Chen JS, Wang YX, Shao L, Pan HX, Li JA, Lin HM, et al. Functional identification of the gene encoding the enzyme involved in mannosylation in ramoplanin biosynthesis in Actinoplanes sp. Biotechnol Lett. 2013; 35: 1501–1508. doi: 10.1007/s10529-013-1233-3 PMID: 23892980

12. McLaughlin, Jr, Russell DW. Molecular Cloning: A Laboratory Manual. 3rd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2001.

13. MacNeil DJ, Gewain KM, Ruby CL, Dezeny G, Gibbons PH, MacNeil T. Analysis of Streptomyces avermitilis genes required for avermectin biosynthesis utilizing a novel integration vector. Gene. 1992; 116: 43–49. PMID: 1628843

14. Butler MS. Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep. 2008; 25: 475–516. doi: 10.1039/b514294f PMID: 18497896

15. Catalano C, Ciabatti R, Kettenring JK, Winters G, Tuan G, Zerilli L, Cavalleri B. Ramoplanin (A-16686), a new glycolipodepsipeptide antibiotic. II. Structure elucidation. J Antibiot (Tokyo). 1989; 42: 254–267. PMID: 2334153

16. Reynolds PE, Somner EA. Comparison of the target sites and mechanisms of action of glycopeptide and lipoglycodepsipeptide antibiotics. Drugs Exp Clin Res. 1990; 16: 385–389. PMID: 2151441

17. Floss HG. Combinatorial biosynthesis-potential and problems. J Biotechnol. 2006; 124: 242–257. PMID: 16414140

18. McLaughlin, Jr, Russell DW. Molecular Cloning: A Laboratory Manual. 3rd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2001.

19. Sheehan SK, Sturz A, Kalbacher H, Klose U, Nagele T, Amin B, et al. Ramoplanin imaging conjugates—synthesis and evaluation. Med Chem. 2014; 10: 18–26. PMID: 23648784

20. Reynolds PE, Somner EA. Comparison of the target sites and mechanisms of action of glycopeptide and lipoglycodepsipeptide antibiotics. Drugs Exp Clin Res. 1990; 16: 385–389. PMID: 2151441

21. Fang X, Niran J, Shin D, Rew Y, Boger DL, Walker S. Functional and biochemical analysis of a key series of ramoplanin analogues. Bioorg Med Chem Lett. 2009; 19: 6189–6191. doi: 10.1016/j.bmcl.2009.09.001 PMID: 19783144
26. Cudic P, Behenna DC, Kranz JK, Kruger RG, Wand AJ, Veklich YI, et al. Functional analysis of the lipo- 
glycodepsipeptide antibiotic ramoplanin. Chem Biol. 2002; 9: 897–906. PMID: 12204689

27. Sievers S, Ernst CM, Geiger T, Hecker M, Wolz C, Becher D, et al. Changing the phospholipid composi- 
tion of Staphylococcus aureus causes distinct changes in membrane proteome and membrane-sen-
sory regulators. Proteomics. 2010; 10: 1685–1693. doi: 10.1002/pmic.200900772 PMID: 20162562

28. Cheng M, Huang JX, Ramu S, Butler MS, Cooper MA. Ramoplanin at bactericidal concentrations 
induces bacterial membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother. 
2014; 58: 6819–6827. doi: 10.1128/AAC.00061-14 PMID: 25182650

29. Yim G, Thaker MN, Koteva K, Wright G. Glycopeptide antibiotic biosynthesis. J Antibiot (Tokyo). 2014; 
67: 31–41.

30. Van Pée KH. Biosynthesis of halogenated metabolites by bacteria. Annu Rev Microbiol. 1996; 50: 
375–399. PMID: 8905085

31. Hayashi N, Nakata Y, Yazaki A. New findings on the structure-phototoxicity relationship and photo-
stability of fluoroquinolones with various substituents at position 1. Antimicrob Agents Chemother. 
2004; 48: 799–803. PMID: 14982767